INIS
breasts
96%
cancer
100%
carcinomas
46%
chemotherapy
22%
comparative evaluations
14%
concentration
11%
cost
15%
drugs
15%
european union
11%
geometry
7%
growth factors
15%
hazards
11%
hormones
15%
humans
15%
metastases
36%
pathology
5%
patients
100%
populations
7%
range
7%
receptors
30%
surgery
21%
therapy
51%
usa
11%
weight
15%
Keyphrases
Advanced Breast Cancer
30%
Breast Cancer Patients
46%
Breast Reconstruction
15%
Cost Savings
15%
Cyclin-dependent Kinase 4 (CDK4)
17%
Dosing Regimen
15%
Ductal Carcinoma in Situ
46%
HER2 Metastatic Breast Cancer
17%
HER2+
15%
HER2-positive
17%
Hormone Receptor-positive
15%
Human Epidermal Growth Factor Receptor 2 (HER2)
23%
In Situ Component
21%
Invasive Breast Cancer
30%
Metastatic Breast Cancer
16%
Neoadjuvant Systemic Therapy
32%
Overall Survival
17%
Pathological Complete Response
17%
Patient Characteristics
15%
Sacituzumab Govitecan
15%
Subnational Analysis
30%
Surgical Prognosis
15%
Survival Characteristics
15%
Survival Treatment
15%
Time Trends
15%
Trastuzumab
15%
Trastuzumab Resistance
15%
Treatment Characteristics
15%
Visceral Crisis
15%
World Time
15%
Medicine and Dentistry
Breast Cancer
46%
Cancer Diagnosis
5%
CDK4/6 Inhibitor
17%
Hormone Receptor
15%
Hormone Therapy
6%
Intraductal Carcinoma
46%
Metastatic Breast Cancer
30%
Neoadjuvant Chemotherapy
15%
Observational Study
15%
Overall Survival
18%
Patient Characteristics
15%
Quadrantectomy
15%
Systemic Therapy
34%
Triple Negative Breast Cancer
15%